Professor Serge Resnikoff MD, PhD, is an international expert and consultant in global public health, ophthalmology, and eye health. He is a conjoint professor at the University of New South Wales in Sydney and teaches in Paris and London. He is also the Chair of the International Myopia Institute board, the President of Organisation pour la Prévention de la Cécité (OPC), the President of Thea Foundation, the Chair of the Brien Holden Vision Foundation and the immediate past chair of the International Coalition for Trachoma Control.
From 2008 to 2010 he served as CEO of Thea, a European pharmaceutical group, specializing in the research, development, and commercialization of eye care products. From 2004 to 2008, he co-ordinated various World Health Organization (WHO) programmes aiming to prevent and manage non-communicable diseases such as cancer, diabetes, and cardiovascular, respiratory, genetic, ear and eye diseases.
From 1999 until 2004, he led the WHO Programme for the Prevention of Blindness and Deafness, which aimed to make essential eye and ear care available to all. Since joining WHO in 1995, he has developed public health strategies and contributed to global partnerships such as VISION 2020, involving governments, academic institutions, non-governmental organizations and private sector groups. Before this, he worked for 14 years in developing countries, mainly in sub-Saharan Africa.
With a PhD from Paris University, an MD from Bordeaux University, and post-graduate degrees in ophthalmology, tropical medicine, air and space medicine, public health, epidemiology, and biostatistics, he has published over 250 refereed articles and book chapters.
Areas of Expertise (6)
Air and Space Medicine
Paris University: Ph.D., Ophthalmology
Bordeaux University: M.D.
- University of New South Wales
- Brien Holden Vision Foundation
- Thea Foundation
- OPC – Organisation pour la Prévention de la Cécité
Media Appearances (4)
Chronic diseases and public health failures fuelling COVID-19 pandemic: study
The latest findings from the Global Burden of Disease Study (GBD) were published this month in The Lancet, providing new insights on how well countries were prepared in terms of underlying health for the COVID-19 pandemic, and setting out the true scale of the challenge to protect against further pandemic threats...
Trachoma: WHO-led alliance awarded for saving the sight of millions
World Health Organization online
The WHO Alliance for the Global Elimination of Trachoma by the year 2020 (GET2020) has been awarded the Global Partnership Award by the International Agency for the Prevention of Blindness. Anthony Solomon, Medical Officer and Secretary GET2020; Dr Astrid Bonfield, Chief Executive, Queen Elizabeth Diamond Jubilee Trust; and Professor Serge Resnikoff, Vice-Chair, International Coalition for Trachoma Control.
First optometrists graduate in Vietnam
Optometry Today online
Senior consultant in international health and development, and former director of the World Health Organization’s (WHO) prevention of blindness and deafness programmes, Dr Serge Resnikoff, said: “The development of the optometry profession is a much needed solution to the inequities in the health care system in Vietnam, especially with respect to the elimination of avoidable blindness due to uncorrected refractive error. Optometrists will in time increase the efficiency of eye services in Vietnam and improve the health system’s cost effectiveness...”
Universal eye health: the fight to save the world’s vision
“Progress made in the elimination of blinding neglected tropical diseases, namely onchocerciasis and trachoma, are probably the most striking success stories of Vision 2020,” says Professor Serge Resnikoff, immediate past chair of the International Coalition for Trachoma Control...
Featured Articles (6)
Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysisGlobal Health
2017 Global and regional prevalence estimates for blindness and vision impairment are important for the development of public health policies. We aimed to provide global estimates, trends, and projections of global blindness and vision impairment.
Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050Ophthalmology
2016 Myopia is a common cause of vision loss, with uncorrected myopia the leading cause of distance vision impairment globally. Individual studies show variations in the prevalence of myopia and high myopia between regions and ethnic groups, and there continues to be uncertainty regarding increasing prevalence of myopia.
Causes of vision loss worldwide, 1990–2010: a systematic analysisGlobal Health
2013 Data on causes of vision impairment and blindness are important for development of public health policies, but comprehensive analysis of change in prevalence over time is lacking.
The number of ophthalmologists in practice and training worldwide: a growing gap despite more than 200 000 practitioners Serge Resnikoff1, William Felch2, Tina-British Journal of Ophthalmology
2012 To assess the current number of ophthalmologists practicing worldwide in 2010 and to create a system for maintaining, collecting and improving the accuracy of data on ophthalmologists per population, ophthalmologists performing surgery, growth rate of the profession, and the number of residents in training.
Estimated number of ophthalmologists worldwide (International Council of Ophthalmology update): will we meet the needs?British Journal of Ophthalmology
2020 To estimate 2015 global ophthalmologist data and analyse their relationship to income groups, prevalence rates of blindness and visual impairment and gross domestic product (GDP) per capita.
IMI-Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic StudiesIOVS
2019 We provide a standardized set of terminology, definitions, and thresholds of myopia and its main ocular complications. Critical review of current terminology and choice of myopia thresholds was done to ensure that the proposed standards are appropriate for clinical research purposes, relevant to the underlying biology of myopia, acceptable to researchers in the field, and useful for developing health policy.